Furthermore, in head-and-neck squamous cell carcinoma, the reduction of Trop-2 expression resulted in sensitivity to anti-HER3 antibodies (58) while in non-small cells lung cancer it was observed that Trop-2 overexpression was linked to the primary resistance to PD-L1 blockade, suggesting an interconnection existing between the two receptors, and thus recommending the administration of combinatorial therapy solely after a Trop-2-based selection (59). This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.